SRP4693
Apolipoprotein A−I human
recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)
Synonym(s):
APOA1, Apo-AI, Apolipoprotein A-I, C117399, MGC117399
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
human
recombinant
expressed in E. coli
assay
≥97% (HPLC)
≥97% (SDS-PAGE)
form
lyophilized
mol wt
~28 kDa
packaging
pkg of 100 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... ApoA1(335)
Looking for similar products? Visit Product Comparison Guide
General description
ApoA-I (apolipoprotein A-I) is a 29.0kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. Recombinant human ApoA-I is a 28.2kDa protein of 244 amino acid residues.
ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.
Application
Apolipoprotein A-I human has been used in the cholesterol efflux assay.
Biochem/physiol Actions
ApoA-I (apolipoprotein A-I), which is found exclusively in HDL (high-density lipoprotein), has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is thought to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. Changes in the level of serum apoA-I may serve as a prognostic marker for non-metastatic nasopharyngeal carcinoma. Low levels of apoA-I in the plasma is linked to hyperhomocysteinemia.
Physical form
Sterile filtered and Lyophilized without additives.
Preparation Note
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
Reconstitution
Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4 °C for 1 week or –20 °C for future use.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Huairui Shi et al.
Scientific reports, 6, 20154-20154 (2016-01-30)
Lanatoside C's impact on atherosclerosis is poorly understood. The present study was conducted to determine whether lanatoside C affects the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. ApoE(-/-) mice were administered either phosphate-buffered saline (PBS) containing 0.1% DMSO (the
Yuanyuan Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(8), 1574-1587 (2019-07-12)
To determine the role of hepatic FOXA3 (forkhead box A3) in lipid metabolism and atherosclerosis. Approach and Results: Hepatic FOXA3 expression was reduced in diabetic or high fat diet-fed mice or patients with nonalcoholic steatohepatitis. We then used adenoviruses to
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.
Gelissen IC
Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 534-540 (2006)
Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
Luo XL, et al.
Oncotarget, 6, 44037-44048 (2015)
Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration.
Jolley CD, et al.
Journal of Lipid Research, 39, 2143-2149 (1998)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service